Evidence-linked · In silico · Synthetic patients only

Oncology Navigator

Powered by AiMOneHealth  ·  My Worksheet →

Interactive decision trainers for 61 cancer types — rehearse real oncology decisions on synthetic patients, with every recommendation traced to a primary source, graded honestly, and stamped with an expiry date. One versioned JSON spec per condition; every app, scenario deck, and credibility file is a build product regenerated from it and gated by conformance tests before release.

Conformancegate · pass232,800 checks · 0 fail

What lives here

61live trainers
1,480graded references
640modeled treatment arms
236clinical-trial doors
677teaching scenarios
677case quizzes
630honesty constraints
232,800conformance checks, 0 failing

Choose a cancer type (61)

Brain & CNS

Glioblastoma, IDH-wildtype (adult)

flagship

gate ✓ 10 props
Blood & marrow

Acute lymphoblastic leukemia (adult)

mixture-cure family · v1.4 upgrade

gate ✓ 12 props
Blood & marrow

Acute lymphoblastic leukemia (children)

first two-developer-era run

gate ✓ 12 props
Blood & marrow

Acute lymphoblastic leukemia (infants <1 yr, KMT2A-rearranged)

the KMT2A biology · the blinatumomab turn

gate ✓ 14 props
Blood & marrow

Acute myeloid leukemia

first factory-built

gate ✓ 10 props
Blood & marrow

Acute promyelocytic leukemia (adult)

the split the aml run opened

gate ✓ 13 props
Blood & marrow

Chronic lymphocytic leukemia

watch-and-wait modeled as a ranked arm

gate ✓ 12 props
Blood & marrow

Chronic myelogenous leukemia

born with the care-delivery layer

gate ✓ 11 props
Blood & marrow

Hairy cell leukemia

the five-day cure, kept honest

gate ✓ 11 props
Blood & marrow

Myelodysplastic neoplasms (MDS, adult)

two goals, one honest scoreboard · the VERONA lesson

gate ✓ 14 props
Blood & marrow

Myeloproliferative neoplasms (PV / ET / myelofibrosis)

the JAK era · the count-control discipline

gate ✓ 13 props
Blood & marrow

MDS/MPN overlap neoplasms (CMML)

the MDS/MPN overlap · the post-HMA cliff

gate ✓ 14 props
Blood & marrow

Multiple myeloma / plasma cell neoplasms

the marathon · ranked only on what has finished aging

gate ✓ 13 props
Blood & marrow

AL (light-chain) amyloidosis

the two-currency disease · the anti-fibril frontier

gate ✓ 13 props
Lymphoma

Classic Hodgkin lymphoma (age >=12)

the scan that removes a drug · Deauville checkpoint

gate ✓ 11 props
Lymphoma

Nodular lymphocyte-predominant B-cell lymphoma (formerly NLPHL)

the renamed entity · the transformation watch

gate ✓ 14 props
Lymphoma

Diffuse large B-cell lymphoma

the 12-month line · three trials, one question, two answers

gate ✓ 14 props
Lymphoma

High-grade B-cell lymphoma with MYC and BCL2 (+/-BCL6) rearrangements (double-hit)

the double-hit entity · FISH decides; no trial ever proved the intensity

gate ✓ 12 props
Lymphoma

Primary mediastinal B-cell lymphoma

the young-mediastinal entity · the radiation-sparing turn

gate ✓ 14 props
Lymphoma

Follicular lymphoma

the scoreboard is burden, not survival · the confirmatory-evidence ledger

gate ✓ 14 props
Lymphoma

Primary cutaneous follicle centre lymphoma

the skin-limited entity · the over-treatment lesson

gate ✓ 12 props
Lymphoma

Primary CNS lymphoma

two currencies: survival and cognition · the steroid trap

gate ✓ 12 props
Breast

Breast cancer (early stage)

the operation is also a readout · pCR-adaptive therapy

gate ✓ 13 props
Breast

Inflammatory breast cancer (nonmetastatic)

the clinical-diagnosis emergency · trimodality non-negotiable

gate ✓ 12 props
Breast

Breast cancer (metastatic)

goals change, honesty doesn't · the HER2-low rewrite

gate ✓ 12 props
Breast

Ductal carcinoma in situ

recurrence is not survival · the watching frontier

gate ✓ 10 props
Lung & thorax

Non-small cell lung cancer

the ticket rack · ten drivers, one panel

gate ✓ 12 props
Lung & thorax

Small cell lung cancer

the anti-ticket-rack · tempo is the biology

gate ✓ 11 props
GI

Colorectal cancer

the ctDNA frontier · organ preservation earned

gate ✓ 12 props
GI

Pancreatic cancer

the resectability fork · the pan-RAS turn

gate ✓ 12 props
GU

Prostate cancer

the risk ladder · the intensification era

gate ✓ 13 props
GU

Bladder cancer

the intravesical era · the EV+P rewrite

gate ✓ 13 props
GU

Kidney (renal cell) cancer

the doublet era · the adjuvant honesty ledger

gate ✓ 13 props
Skin

Melanoma

the immunotherapy flagship · the neoadjuvant turn

gate ✓ 13 props
Skin

Basal cell skin cancer

the commonest cancer · the rarest killer

gate ✓ 12 props
Skin

Squamous cell skin cancer

the dangerous sibling · the transplant multiplier

gate ✓ 14 props
Skin

Merkel cell carcinoma

the virus-made skin cancer · the IO-first chapter

gate ✓ 14 props
Gynecologic

Ovarian / fallopian tube / primary peritoneal

the PARP maintenance era · the HRD fork

gate ✓ 13 props
Gynecologic

Endometrial (uterine) cancer

the molecular reclassification · the dMMR-IO era

gate ✓ 13 props
Gynecologic

Uterine sarcoma

the accidental diagnosis · histology is the disease

gate ✓ 12 props
Gynecologic

Cervical cancer

the preventable disease · the chemoradiation-IO turn

gate ✓ 13 props
Head, neck & endocrine

Head and neck squamous cancers

the HPV fork · the de-escalation frontier

gate ✓ 14 props
Head, neck & endocrine

Thyroid cancer

the good-prognosis trap · watching earned its trial

gate ✓ 13 props
GI

Esophageal cancer

the trimodality standard · the adjuvant-IO turn

gate ✓ 15 props
GI

Gastric (stomach) cancer

the perioperative backbone · the biomarker quartet

gate ✓ 15 props
GI

Hepatocellular (liver) cancer

the two-disease problem · the IO-doublet era

gate ✓ 14 props
GI

Bile duct / gallbladder cancer

the anatomy-split family · the actionable-alteration surprise

gate ✓ 13 props
GI

Anal cancer

the surgery-sparing original · the HPV receipt

gate ✓ 14 props
GI

Appendiceal cancer

the incidental diagnosis · grade is destiny

gate ✓ 12 props
GU

Testicular cancer

the curable archetype · surveillance is a spine

gate ✓ 13 props
Bone & soft tissue

Soft tissue sarcoma

seventy diseases in a trench coat · histology routes everything

gate ✓ 12 props
GI

Gastrointestinal stromal tumor

the targeted-therapy original · genotype is the dose

gate ✓ 12 props
Bone & soft tissue

Osteosarcoma

the forty-year plateau · MAP and the honest map

gate ✓ 13 props
Bone & soft tissue

Ewing sarcoma

the fusion-defined bone cancer · every-two-weeks won its trial

gate ✓ 13 props
Lung & thorax

Mesothelioma

the exposure-made cancer · the IO-doublet rewrite

gate ✓ 13 props
GI

Gastrointestinal neuroendocrine tumors

the slow cancer with a clock of its own · grade routes everything

gate ✓ 13 props
GI

Pancreatic neuroendocrine tumors

the functional-syndrome family · where sunitinib lives

gate ✓ 13 props
Cross-cutting

Carcinoma of unknown primary

the diagnosis that is a process · tissue-of-origin meets the panel era

gate ✓ 13 props
Lung & thorax

Thymoma and thymic carcinoma

the two-disease mediastinum · the same drug, two verdicts

gate ✓ 12 props
Head, neck & endocrine

Adrenal tumors (adrenocortical, pheo/paraganglioma)

the hormone-first gland · mitotane and the metanephrine rule

gate ✓ 13 props
GI

Small bowel adenocarcinoma

first bottom-up run (Pardha)

gate ✓ 14 props
No trainer matches — try a broader term, or pick a category above.
conformance ledger — 776 properties across 61 trainers, 0 failures (300 seeded Monte-Carlo trials per property)
trainerpropertiestrials eachfailuressource
gbm-idh-wildtype 10300 0 NCI ↗
all-adult 12300 0 NCI ↗
all-pediatric 12300 0 NCI ↗
all-infant 14300 0 NCI ↗
aml 10300 0 NCI ↗
apl 13300 0 NCI ↗
cll 12300 0 NCI ↗
cml 11300 0 NCI ↗
hairy-cell 11300 0 NCI ↗
mds 14300 0 NCI ↗
mpn 13300 0 NCI ↗
cmml 14300 0 NCI ↗
myeloma 13300 0 NCI ↗
al-amyloidosis 13300 0 NCI ↗
hodgkin 11300 0 NCI ↗
nlpbl 14300 0 NCI ↗
dlbcl 14300 0 NCI ↗
hgbl 12300 0 NCI ↗
pmbcl 14300 0 NCI ↗
follicular 14300 0 NCI ↗
pcfcl 12300 0 NCI ↗
cns-lymphoma 12300 0 NCI ↗
breast-early 13300 0 NCI ↗
inflammatory-breast 12300 0 NCI ↗
breast-metastatic 12300 0 NCI ↗
dcis 10300 0 NCI ↗
nsclc 12300 0 NCI ↗
sclc 11300 0 NCI ↗
colorectal 12300 0 NCI ↗
pancreatic 12300 0 NCI ↗
prostate 13300 0 NCI ↗
bladder 13300 0 NCI ↗
kidney-rcc 13300 0 NCI ↗
melanoma 13300 0 NCI ↗
skin-bcc 12300 0 NCI ↗
skin-scc 14300 0 NCI ↗
merkel 14300 0 NCI ↗
ovarian 13300 0 NCI ↗
endometrial 13300 0 NCI ↗
uterine-sarcoma 12300 0 NCI ↗
cervical 13300 0 NCI ↗
head-neck 14300 0 NCI ↗
thyroid 13300 0 NCI ↗
esophageal 15300 0 NCI ↗
gastric 15300 0 NCI ↗
hcc 14300 0 NCI ↗
biliary 13300 0 NCI ↗
anal 14300 0 NCI ↗
appendiceal 12300 0 NCI ↗
testicular 13300 0 NCI ↗
sts 12300 0 NCI ↗
gist 12300 0 NCI ↗
bone-osteo 13300 0 NCI ↗
bone-ewing 13300 0 NCI ↗
mesothelioma 13300 0 NCI ↗
gi-net 13300 0 NCI ↗
pnet 13300 0 NCI ↗
cup 13300 0 NCI ↗
thymoma 12300 0 NCI ↗
adrenal 13300 0 NCI ↗
small-intestine 14300 0 NCI ↗

Why this toolset

Every claim carries a receipt.

1,480 graded references resolve to primary sources — PubMed, ClinicalTrials.gov, FDA. Verbatim quotes are marked verbatim; secondhand claims say so; nothing is silently rounded up.

Tested like software, because it is.

776 behavioral properties run 300 seeded Monte-Carlo trials each — 232,800 checks with 0 failures — plus golden-vector parity between the test suite and the app engine. The gate blocks release; CI enforces it.

Evidence expires; this registry knows.

Every spec carries review dates and a weekly refresh cycle. Trial-door statuses are verified against the registry firsthand and stamped. When evidence reverses, the reversal is kept as a teaching case — never silently deleted.

Honesty constraints render verbatim.

630 constraints — negative trials, harm signals, contested rituals, look-alike traps — print in the trainers exactly as written and are never relaxed.

A connected registry, not 61 silos.

Look-alike diagnoses reroute live to the right trainer — double-expressor to DLBCL, double-hit back again; the borders between entities are taught, not blurred.

Synthetic by design.

No PHI anywhere. 677 scenarios and 677 quizzes are generated from the same spec that builds each app, so the teaching cases and the engine can never drift apart. Not medical advice.

How to use it: pick a cancer type above, set the synthetic patient’s findings (diagnosis confirmation, fitness, biomarkers), and watch the decision landscape re-rank live — with gates that refuse to rank until the workup earns it, outcome numbers tied to their trials, co-intervention and care-delivery layers, and quiz decks that interrogate the reasoning. Built for clinicians in training, tumor-board rehearsal, and patient-conversation prep.